Biotech
Mammoth Biosciences
Mammoth Biosciences raises $195M Series D at $1B valuation
$195M
Total Raised
Series D
Latest Round
2017
Founded
150+
Employees
3478 Buskirk Avenue, Pleasant Hill, CA 94523
1 min read
Quick Facts
Valuation
$1B
Latest Round Size
$195M
Latest Round Date
August 2024
Mammoth Biosciences: Series D Funding Round
Mammoth Biosciences has successfully raised $195M in Series D funding, reaching a valuation of $1B.
Company Overview
CRISPR-based diagnostics and therapeutics
Funding Details
The Series D round was led by Decheng Capital, with participation from Greenoaks Capital, Mayfield, NFX, 8VC, Plum Alley Ventures.
Company Information
- Headquarters: 3478 Buskirk Avenue, Pleasant Hill, CA 94523
- Founded: 2017
- Employees: 150+
- Category: Biotech
Investment
Mammoth Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Decheng Capital: Verified investor in Series D
- Greenoaks Capital: Verified investor in Series D
- Mayfield: Verified investor in Series D
- NFX: Verified investor in Series D
- 8VC: Verified investor in Series D
- Plum Alley Ventures: Verified investor in Series D
Key Investors
Decheng Capital
Lead Investor
Verified investor in Series D
Greenoaks Capital
Investor
Verified investor in Series D
Mayfield
Investor
Verified investor in Series D
NFX
Investor
Verified investor in Series D
8VC
Investor
Verified investor in Series D
Plum Alley Ventures
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M